TY - JOUR
T1 - Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors
AU - Van Londen, G. J.
AU - Beckjord, E. B.
AU - Dew, M. A.
AU - Cooper, K. L.
AU - Davidson, N. E.
AU - Bovbjerg, D. H.
AU - Donovan, H. S.
AU - Thurston, R. C.
AU - Morse, J. Q.
AU - Nutt, S.
AU - Rechis, R.
N1 - Funding Information:
Acknowledgments We are grateful to Ms. A. Cardy for her critical reading and editing of this manuscript. Research reported in this publication was supported in part by the National Institutes of Health (KL2TR000146; P30 AG024827; P30 CA047904), the Hartford Foundation, Magee-Women’s Research Institute & Foundation, and the Pittsburgh Affiliate of Susan G. Komen for the Cure.
PY - 2014/4
Y1 - 2014/4
N2 - Background: Breast cancer survivors often receive long-term adjuvant endocrine therapy (AET) to reduce recurrence risk. Adherence to AET is suboptimal, which may be due to the experience of symptoms and/or concerns. Few studies have comprehensively assessed self-reported concerns between those who currently, previously or have never received AET. The study objective is to describe self-reported physical and emotional concerns of breast cancer survivors who are current, prior, or never-recipients of AET. Methods: Secondary analysis was performed on a subset of survey data collected in the 2010 LIVESTRONG Survey. Breast cancer survivors (n=1,013, mean 5.4 years post-diagnosis) reported on 14 physical and eight emotional concerns that began after diagnosis and were experienced within 6 months of participation in the survey. Bivariate analyses examined the prevalence of each concern by AET status. The relationships between AET and burden of physical or emotional concerns were modeled with logistic regression. Results: More than 50 % of the participants reported currently experiencing cognitive issues, fatigue, fear of recurrence, emotional distress, and identity/grief issues. Thyroid dysfunction and stigma concerns were more common among participants with prior AET (p<0.01), while fear of recurrence, emotional distress, and concern about appearance were more common among those currently receiving AET (p<0.01). Fatigue, sexual dysfunction, and pain were more common among prior and current AET recipients (p<0.01). In adjusted models, receipt of AET was associated with a higher number of physical, but not emotional concerns. A higher number of concerns was associated with younger age, having children, receipt of chemotherapy, longer duration of cancer treatment, and shorter time since diagnosis (p<0.01). Conclusions: Breast cancer survivors who received AET were at risk of developing a variety of physical and emotional concerns, many of which persisted after treatment. These findings suggest the importance of developing individualized, supportive resources for breast cancer survivors.
AB - Background: Breast cancer survivors often receive long-term adjuvant endocrine therapy (AET) to reduce recurrence risk. Adherence to AET is suboptimal, which may be due to the experience of symptoms and/or concerns. Few studies have comprehensively assessed self-reported concerns between those who currently, previously or have never received AET. The study objective is to describe self-reported physical and emotional concerns of breast cancer survivors who are current, prior, or never-recipients of AET. Methods: Secondary analysis was performed on a subset of survey data collected in the 2010 LIVESTRONG Survey. Breast cancer survivors (n=1,013, mean 5.4 years post-diagnosis) reported on 14 physical and eight emotional concerns that began after diagnosis and were experienced within 6 months of participation in the survey. Bivariate analyses examined the prevalence of each concern by AET status. The relationships between AET and burden of physical or emotional concerns were modeled with logistic regression. Results: More than 50 % of the participants reported currently experiencing cognitive issues, fatigue, fear of recurrence, emotional distress, and identity/grief issues. Thyroid dysfunction and stigma concerns were more common among participants with prior AET (p<0.01), while fear of recurrence, emotional distress, and concern about appearance were more common among those currently receiving AET (p<0.01). Fatigue, sexual dysfunction, and pain were more common among prior and current AET recipients (p<0.01). In adjusted models, receipt of AET was associated with a higher number of physical, but not emotional concerns. A higher number of concerns was associated with younger age, having children, receipt of chemotherapy, longer duration of cancer treatment, and shorter time since diagnosis (p<0.01). Conclusions: Breast cancer survivors who received AET were at risk of developing a variety of physical and emotional concerns, many of which persisted after treatment. These findings suggest the importance of developing individualized, supportive resources for breast cancer survivors.
KW - Adjuvant endocrine therapy
KW - Adverse effects
KW - Breast cancer survivor
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=84895880889&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895880889&partnerID=8YFLogxK
U2 - 10.1007/s00520-013-2041-y
DO - 10.1007/s00520-013-2041-y
M3 - Article
C2 - 24271937
AN - SCOPUS:84895880889
SN - 0941-4355
VL - 22
SP - 937
EP - 945
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 4
ER -